HCA Narrows Revenue View to $77B-$79.5B, Trims EPS Outlook
HCA is trading near its 52-week low of $330 (15% above the low).
Summary
HCA Healthcare tightened its full-year revenue guidance to $77.0B-$79.5B from $76.5B-$80.0B while reiterating the lowered EPS range of $28.70-$30.50, down from $29.10-$31.50. The revenue midpoint is essentially unchanged, but the narrower band reduces uncertainty. The company also declared a $0.78 quarterly dividend, payable September 30. This follows the July 14 pre-announcement that cut EPS guidance on rising uncompensated care costs as ACA subsidies expire. Shares are up 1.7% pre-market, suggesting the market had already priced in the guidance cut and is focusing on the solid Q2 beat and dividend.
At the time of this announcement, HCA was trading at $379.20 on NYSE in the Life Sciences sector, with a market capitalization of approximately $83.5B. The 52-week trading range was $330.00 to $556.52. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: dpa-AFX.